FDA Recall D-0619-2021

Novo Nordisk Inc · Plainsboro, NJ

Class I — life-threatening Terminated 627 days on record

Highest impact — Class I recall — FDA determination of strong likelihood of serious adverse health consequence or death.

Product

TRESIBA FlexTouch (insulin degludec injection) 100 units/mL (U-100), 3 mL Prefilled Pen, Sample, Rx only, Manufactured by: Novo Nordisk A/S, Bagsvaerd, Denmark, Distributed by: Movo Mordisk Inc., Plainsboro, NJ 08536, NDC 0169-2660-90 (Pen), NDC 0169-2660-97 (Kit)

Lot / code: JP52771 exp 09/30/2021; JP53136 exp 06/30/2021; KP50575 exp 01/31/2022; KP50976 exp 01/31/2022; KP51813 exp 04/30/2022; KP52035 exp 04/30/2022; KP52117 exp 04/30/2022; KP52440 exp 06/30/2022; KP52461 exp 04/30/2022; KP52616 exp 06/30/2022; JP52361 exp 08/01/2021

Quantity: N/A

Reason for recall

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Recall record

Recall number: D-0619-2021
Classification: Class I
Status: Terminated
Voluntary or mandated: Voluntary: Firm initiated
Firm notification: Letter
Distribution: Nationwide in the USA
Recall initiated: 2021-03-22
Classified by FDA Center: 2021-06-10
FDA published: 2021-04-21
Terminated: 2022-12-09
Recalling firm: Novo Nordisk Inc
Firm location: Plainsboro, NJ

Drug identification

Brand name(s): TRESIBA
Generic name(s): INSULIN DEGLUDEC
Manufacturer(s): Novo Nordisk
NDC(s): 0169-2550, 0169-2660, 0169-2662
Route(s): SUBCUTANEOUS

‹ All recalls